No Data
Chenguang Biotech Group (300138.SZ): The subsidiary has been recognized as a high-tech enterprise.
On December 26, Gelonghui reported that Chenguang Biotech Group (300138.SZ) announced that according to the notice released on December 26, 2024, by the Office of the National High-Tech Enterprise Recognition Management Leading Group, the wholly-owned subsidiary of Chenguang Biotech Group Co., Ltd. — Guiyang Chenguang Biotech Co., Ltd. has been included in the first batch of high-tech enterprises recognized and reported by Guizhou Province in 2024, passing the high-tech enterprise recognition with certificate number: GR202452000132; issued.
Chenguang Biotech Group (300138.SZ): Plans to change part of the use of raised funds.
Gelonghui, on December 26, announced that Chenguang Biotech Group (300138.SZ) disclosed that, according to the company's development plan, in order to improve the efficiency of fundraising, it intends to change the use of part of the funds raised from the public issuance of convertible Bonds. A portion of the raised funds amounting to 45 million yuan originally allocated for the "Integrated Natural Plant Extraction Project (Phase I)" will be redirected for the "Health Food Construction Project of Chenguang Biotech Group Handan Co., Ltd.".
chenguang biotech group (300138.SZ): Currently no fertilizer business
Glonghui reported on November 28 that chenguang biotech group (300138.SZ) stated on the investor interaction platform that the company currently has no business in fertilizers. The byproducts such as residue from the production processes of the company's lutein and stevia products can be used as raw materials for downstream fertilizer companies.
chenguang biotech group (300138.SZ): The main sugar substitute product is stevia sugar, with a current production capacity of 2000 tons per year.
Gelonghui November 11th | Chenguang Biotech Group (300138.SZ) stated on the investor interaction platform that the company's sugar substitute products are mainly stevia sugar, with a current production capacity of 2000 tons/year. The products have a production cost advantage and yield is in a leading position in the industry.
Chenguang Biology: Report for the third quarter of 2024
Chenguang Biotech Group (300138.SZ) released its performance for the first three quarters, with a net income of 62.6059 million yuan, a decrease of 84.28%.
Chenguang Biotech Group (300138.SZ) released the third quarter report of 2024, with the company's revenue for the first three quarters at 5...
ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) Low P/E No Reason For Excitement